C83.62 Undifferentiated (diffuse) non-Hodgkin's lymphoma, intrathoracic lymph nodes

Name of the Condition

• Undifferentiated (diffuse) non-Hodgkin's lymphoma, intrathoracic lymph nodes
• Also known as ICD-10 code C83.62

Summary

Undifferentiated (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of lymphoid cells that lack distinct differentiation or follicular structure. It typically involves abnormal growth of B-cells or T-cells in lymph nodes or other lymphoid tissues, with a diffuse pattern of spread. This condition specifically affects the intrathoracic lymph nodes and is part of the broader category of non-follicular lymphomas.

Causes

The exact cause of undifferentiated (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in the chest area.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.
• Persistent cough or shortness of breath (if lymph nodes compress airways).

Diagnosis

Diagnosis involves a combination of physical examination, imaging tests (e.g., CT or PET scans) to identify affected areas, biopsy of lymph nodes or tissues for laboratory analysis, and blood tests to assess overall health and detect abnormal cell markers. A definitive diagnosis requires histopathological confirmation of the lymphoma subtype.

Treatment Options

• Chemotherapy: Systemic drugs to target and kill cancer cells.
• Immunotherapy: Uses the body's immune system to fight cancer cells.
• Radiation Therapy: High-energy radiation to target localized tumors.
• Stem Cell Transplant: For aggressive or relapsed cases.
• Targeted Therapy: Drugs that target specific cancer cell characteristics.

Prognosis and Follow-Up

Prognosis varies based on the subtype, stage, and patient factors. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or progression. Treatment response and long-term survival depend on individual case characteristics.

Complications

• Lymph node compression of nearby structures (e.g., airways, blood vessels).
• Increased risk of infections due to impaired immune function.
• Potential for transformation to a more aggressive lymphoma subtype.
• Side effects from treatment, such as fatigue, nausea, or organ toxicity.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid exposure to known carcinogens, such as tobacco or industrial chemicals.
• Manage chronic infections (e.g., HIV, hepatitis) with appropriate medical care.
• Stay up-to-date with vaccinations to reduce infection risk.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, night sweats, or respiratory symptoms (e.g., cough, shortness of breath). Early evaluation is critical for timely diagnosis and management.

Tips for Medical Coders

When coding for C83.62, ensure the documentation specifies "intrathoracic lymph nodes" to confirm the site. Verify that the diagnosis aligns with the clinical findings and that no other site-specific codes are applicable. Document the histopathological confirmation of undifferentiated (diffuse) non-Hodgkin's lymphoma to support code assignment.